NHS-Galleri Linked to Delays
Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.
By
Andrea Surnit
June 4, 2026
Clinical Scorecard: NHS-Galleri Linked to Delays
At a Glance
Category Detail
Condition Key Mechanisms Participation in the NHS-Galleri trial associated with increased diagnostic delays for certain cancers. Target Population Care Setting
Key Highlights
Modest increase in diagnostic delay rates observed in participating regions. Average time to diagnostic resolution increased by about 2 days in participating regions. 9,591 additional referrals experienced diagnostic delay during the first year of the trial. Trial did not meet its primary endpoint of reducing combined stage III-IV cancer. Guideline-Based Recommendations
Diagnosis
Monitor diagnostic delay rates in regions participating in trials. Management
Consider downstream capacity needs when implementing MCED testing. Monitoring & Follow-up
Evaluate the impact of trial participation on routine diagnostic services. Risks
Be aware of potential harms such as false reassurance and diagnostic cascades. Patient & Prescribing Data
Estimated nationwide rollout would cost about $19.2 billion annually for testing alone.
Clinical Best Practices
Assess socioeconomic factors in regions participating in trials. Ensure adequate healthcare staffing in regions implementing new screening tests. Related Resources & Content
